Scroll

latanoprost 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
prostaglandins	1551	130209-82-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: roclanda latanoprost xalatan (15R)-Latanoprost PhXA41	A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA. Molecular weight: 432.60 Formula: C26H40O5 CLOGP: 3.60 LIPINSKI: 0 HAC: 5 HDO: 3 TPSA: 86.99 ALOGS: -4.53 ROTB: 14 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

roclanda
latanoprost
xalatan
(15R)-Latanoprost
PhXA41

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Molecular weight: 432.60
Formula: C26H40O5
CLOGP: 3.60
LIPINSKI: 0
HAC: 5
HDO: 3
TPSA: 86.99
ALOGS: -4.53
ROTB: 14

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Show entries

Search:

Property	Value	Reference
CL (Clearance)	6.70 mL/min/kg	Lombardo F, Berellini G, Obach RS
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
t_half (Half-life)	0.28 hours	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.10 %	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.05 mg/mL	Benet LZ, Broccatelli F, Oprea TI

Showing 1 to 5 of 5 entries

Previous1Next

Approvals:

Show entries

Search:

Date	Agency	Company	Orphan
Jan. 7, 2021	EMA	AERIE PHARMACEUTICALS IRELAND LIMITED
June 5, 1996	FDA	PHARMACIA AND UPJOHN

Showing 1 to 2 of 2 entries

Previous1Next

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Eye irritation	1289.46	12.28	479	35145	21492	63431906
Treatment failure	1013.05	12.28	859	34765	198184	63255214
Intraocular pressure increased	840.85	12.28	253	35371	5825	63447573
Eye pain	523.21	12.28	291	35333	33563	63419835
Glaucoma	516.80	12.28	239	35385	18666	63434732
Ocular hyperaemia	472.07	12.28	246	35378	24898	63428500
Visual acuity reduced	225.86	12.28	145	35479	21681	63431717
Eye pruritus	180.81	12.28	119	35505	18552	63434846
Colitis microscopic	174.10	12.28	91	35533	9248	63444150
Vision blurred	161.39	12.28	227	35397	91697	63361701

Showing 1 to 10 of 252 entries

Previous1 2 3 4 5…26Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Treatment failure	1037.11	12.65	521	20394	46176	34889840
Intraocular pressure increased	751.93	12.65	229	20686	5154	34930862
Eye irritation	570.84	12.65	202	20713	7359	34928657
Eye pain	217.94	12.65	122	20793	13340	34922676
Ocular hyperaemia	202.46	12.65	110	20805	11342	34924674
Visual acuity reduced	189.75	12.65	119	20796	16030	34919986
Glaucoma	173.23	12.65	84	20831	6828	34929188
Vision blurred	135.75	12.65	152	20763	45811	34890205
Foreign body sensation in eyes	114.78	12.65	33	20882	601	34935415
Product delivery mechanism issue	107.53	12.65	24	20891	144	34935872

Showing 1 to 10 of 129 entries

Previous1 2 3 4 5…13Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Intraocular pressure increased	952.05	11.33	303	42235	8902	79692948
Eye irritation	841.32	11.33	341	42197	20340	79681510
Glaucoma	483.99	11.33	228	42310	19533	79682317
Eye pain	354.23	11.33	231	42307	37347	79664503
Visual acuity reduced	327.35	11.33	201	42337	29268	79672582
Ocular hyperaemia	314.88	11.33	193	42345	28013	79673837
Cataract	159.71	11.33	181	42357	61939	79639911
Vision blurred	155.44	11.33	234	42304	105664	79596186
Colitis microscopic	136.52	11.33	80	42458	10688	79691162
Corneal oedema	116.14	11.33	46	42492	2574	79699276

Showing 1 to 10 of 277 entries

Previous1 2 3 4 5…28Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	S01EE01	SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Prostaglandin analogues
ATC	S01EE51	SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Prostaglandin analogues
CHEBI has role	CHEBI:23018	EC 4.2.1.1 inhibitor
CHEBI has role	CHEBI:35674	antihypertensive drugs
CHEBI has role	CHEBI:39456	antiglaucoma agent
CHEBI has role	CHEBI:50266	Prodrugs
FDA CS	M0017805	Prostaglandins
FDA EPC	N0000175454	Prostaglandin Analog
MeSH PA	D009883	Ophthalmic Solutions
MeSH PA	D019999	Pharmaceutical Solutions

Showing 1 to 10 of 10 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Ocular hypertension	indication	4210003	DOID:9282
Open-angle glaucoma	indication	84494001	DOID:1067
Conjunctivitis	contraindication	9826008	DOID:6195
Aphakia	contraindication	24010005
Macular retinal edema	contraindication	37231002	DOID:4449
Iritis	contraindication	65074000	DOID:1406
Pseudophakia	contraindication	95217000
Uveitis	contraindication	128473001	DOID:13141
Cystoid macular edema	contraindication	193387007	DOID:4447
Disorder of macula of retina	contraindication	312999006

Showing 1 to 10 of 10 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
0.005%	XELPROS	SUN PHARM	N206185	Sept. 12, 2018	RX	EMULSION	OPHTHALMIC	9539262	Oct. 15, 2028	REDUCING ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
0.005%;EQ 0.02% BASE	ROCKLATAN	ALCON LABS INC	N208259	March 12, 2019	RX	SOLUTION/DROPS	OPHTHALMIC	10532993	July 11, 2026	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
0.005%;EQ 0.02% BASE	ROCKLATAN	ALCON LABS INC	N208259	March 12, 2019	RX	SOLUTION/DROPS	OPHTHALMIC	10882840	July 11, 2026	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
0.005%;EQ 0.02% BASE	ROCKLATAN	ALCON LABS INC	N208259	March 12, 2019	RX	SOLUTION/DROPS	OPHTHALMIC	11021456	July 11, 2026	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
0.005%;EQ 0.02% BASE	ROCKLATAN	ALCON LABS INC	N208259	March 12, 2019	RX	SOLUTION/DROPS	OPHTHALMIC	8450344	July 11, 2026	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
0.005%;EQ 0.02% BASE	ROCKLATAN	ALCON LABS INC	N208259	March 12, 2019	RX	SOLUTION/DROPS	OPHTHALMIC	9096569	July 11, 2026	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
0.005%;EQ 0.02% BASE	ROCKLATAN	ALCON LABS INC	N208259	March 12, 2019	RX	SOLUTION/DROPS	OPHTHALMIC	10174017	Jan. 27, 2030	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
0.005%;EQ 0.02% BASE	ROCKLATAN	ALCON LABS INC	N208259	March 12, 2019	RX	SOLUTION/DROPS	OPHTHALMIC	10654844	Jan. 27, 2030	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
0.005%;EQ 0.02% BASE	ROCKLATAN	ALCON LABS INC	N208259	March 12, 2019	RX	SOLUTION/DROPS	OPHTHALMIC	11028081	Jan. 27, 2030	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
0.005%;EQ 0.02% BASE	ROCKLATAN	ALCON LABS INC	N208259	March 12, 2019	RX	SOLUTION/DROPS	OPHTHALMIC	11618748	Jan. 27, 2030	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE

Showing 1 to 10 of 14 entries

Previous1 2Next

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Prostaglandin F2-alpha receptor	GPCR	P43088	PF2R_HUMAN	AGONIST	Ki	6.30	IUPHAR	CHEMBL
Prostaglandin E2 receptor EP1 subtype	GPCR	P34995	PE2R1_HUMAN		Ki	5.76	PDSP
Prostaglandin E2 receptor EP3 subtype	GPCR	P43115	PE2R3_HUMAN		Ki	5.19	PDSP
Prostaglandin F2-alpha receptor	GPCR		PF2R_BOVIN		Ki	7.01	CHEMBL

Showing 1 to 4 of 4 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
006059	NDDF
108838001	SNOMEDCT_US
153159	RXNORM
386926002	SNOMEDCT_US
4020967	VUID
4020967	VANDF
41639-83-2	SECONDARY_CAS_RN
4959	MMSL
52442	MMSL
5311221	PUBCHEM_CID

Showing 1 to 10 of 26 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
LATANOPROST	HUMAN PRESCRIPTION DRUG LABEL	1	17478-625	SOLUTION/ DROPS	50 ug	OPHTHALMIC	ANDA	25 sections
Latanoprost	HUMAN PRESCRIPTION DRUG LABEL	1	21695-986	SOLUTION/ DROPS	50 ug	OPHTHALMIC	ANDA	26 sections
Latanoprost	HUMAN PRESCRIPTION DRUG LABEL	1	24208-463	SOLUTION/ DROPS	50 ug	OPHTHALMIC	ANDA	24 sections
Latanoprost	HUMAN PRESCRIPTION DRUG LABEL	1	24208-463	SOLUTION/ DROPS	50 ug	OPHTHALMIC	ANDA	24 sections
Latanoprost	HUMAN PRESCRIPTION DRUG LABEL	1	24208-463	SOLUTION/ DROPS	50 ug	OPHTHALMIC	ANDA	24 sections
Latanoprost	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1920	SOLUTION/ DROPS	50 ug	OPHTHALMIC	ANDA	24 sections
Latanoprost	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1920	SOLUTION/ DROPS	50 ug	OPHTHALMIC	ANDA	24 sections
Latanoprost	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6254	SOLUTION/ DROPS	50 ug	OPHTHALMIC	ANDA	26 sections
LATANOPROST	HUMAN PRESCRIPTION DRUG LABEL	1	55545-1010	SOLUTION	50 ug	OPHTHALMIC	ANDA	24 sections
Latanoprost	HUMAN PRESCRIPTION DRUG LABEL	1	59762-0333	SOLUTION	50 ug	OPHTHALMIC	NDA AUTHORIZED GENERIC	25 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next